Biological drugs: a fact

Nowadays, 50% of drugs in development have a biological origin, according to Farmaindustria. They are a new generation of substances that improve the features of traditional medicines (chemically-based ones) and are intended –most of them- to fight diseases in a more specific way.

The advances in genetic knowledge and the application of new technologies to health make possible the scientific research to take important steps in this way. In fact, these compounds are already gaining ground to the traditional medicines in the worldwide market.

Chronic diseases such as the Rheumatoid Arthritis, for instance, are one of the main fields of influence of these state-of-the-art drugs that, besides, can be personalized. Other relevant field are the vaccines, very necessary to eradicate lethal diseases in humans and animals.

These are some of the advantages of biological drugs:

-They are more specific.

-Their action is usually faster.

-Their response is more time sustained.

-They improve the patient’s quality of life.

Bionaturis operates in the biological arena with the global vision of making those state-of-the-art medicines reach more and more people and producers.

If you want to know more about the advantages of biological drugs, please click in these links

What are biologics? Questions and answers

How drugs and biologics differ?

European Medicine Agency: main guidelines about biologics

September 2nd, 2014|Blog english|Comments Off|

Spanish Pharmaceutical industry bets on research

The Spanish pharmaceutical industry keeps betting on research with an investment of 972 million Euros in 2012. Namely, the investment reached 200 million Euros at the biotechnology sector, 20% of the total budget.

The most important allocation -479 million- was dedicated to clinical trials, most of them in clinical phase III. It must be highlighted that the expense in clinical research has increased 86% in the last nine years. 45% of the budget was dedicated to research contracts with hospitals, universities and public institutions, an activity that increased nearly 5% in 2012.

According to the data of the survey made to members of Farmaindustria, the number of R&D hiring decreased 3,6% in relation to 2011. However, the qualification of the employees is getting higher and higher: four out of five are graduates and doctors. In general figures, Spain is the fourth country in Europe in pharmaceutical workforce with nearly 40,000 jobs.

These data show that, in spite of the present economic situation and the measures of control of expenses, the pharmaceutical industry is still one of the main driving forces of  Spanish R&D. 

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.